GlassScriptPhysician profile
Charles Hodge
NPI 1811949027
$34,299.21
in general payments reported to CMS, 2019-2025
26 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,650 · 2021: $5,018 · 2022: $2,693 · 2023: $1,142 · 2024: $7,949 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,600 · Food and Beverage: $1,602 · Travel and Lodging: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,600.00 |
| Food and Beverage | $1,602.19 |
| Travel and Lodging | $359.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25,515.08 | 2019-2025 | Imfinzi |
| Icad, INC | $6,500.00 | 2020-2021 | |
| Siemens Medical Solutions USA, INC. | $1,125.91 | 2022-2025 | Varian Ethos Treatment Planning |
| Endomagnetics LTD | $186.18 | 2023 | Magseed, Magtrace |
| Gilead Sciences, INC. | $120.37 | 2022 | |
| Brainlab, INC. | $90.47 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Novartis Pharmaceuticals Corporation | $77.09 | 2025 | |
| Elekta, INC. | $76.87 | 2023 | Elekta Medical Linear Accelerator |
| Napo Pharmaceuticals INC | $55.35 | 2024-2025 | Gelclair Concentrated Oral Gel |
| Blue Earth Diagnostics | $53.39 | 2024-2025 | Posluma |
| Takeda Pharmaceuticals U.S.A., INC. | $49.70 | 2024-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $47.24 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Sumitomo Pharma America, INC. | $46.12 | 2023-2024 | Orgovyx |
| Novocure INC. | $42.47 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Pfizer INC. | $38.76 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $38.35 | 2023-2024 | Enhertu |
| Janssen Biotech, INC. | $38.18 | 2022 | |
| Viewray Technologies INC | $31.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.38 | 2022 | |
| Genentech USA, INC. | $25.73 | 2023 | Polivy |
| Tersera Therapeutics LLC | $25.19 | 2023 | Zoladex |
| Tolmar, INC. | $18.58 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $18.58 | 2025 | Rubraca |
| Medtronic, INC. | $18.04 | 2021 | |
| Dendreon Pharmaceuticals LLC | $17.41 | 2023 | Provenge |
| Boston Scientific Corporation | $15.91 | 2025 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.